• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 4: Valuation Model for TEN IP Asset Classes

Part 4: Valuation Model for TEN IP Asset Classes

Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP

Curator: Aviva Lev-Ari, PhD, RN

Chart 3 in Appendix #22 in 2.0 Master Deck – Grand Total Enterprise Value

Component

Value % of Grand Total

Key Driver

Base Portfolio (Pre-2026, non-COM) Confidential Confidential 10 Digital IP Asset Classes + Intangibles
COM Parts 1–9 (Pre-2026) Confidential Confidential Foundational Tool Factory
COM Parts 10–17 (2026 & Beyond) Confidential Confidential Advanced layers
13 Hidden Gems Revival Confidential Confidential Revival and spin-off potential
Three-Legged Stool Strategy Confidential Confidential AJAUS + SLM + spin-off ecosystem
Vertical Integration Moat Premium Confidential Confidential Synergistic effects
Founder Bio / Aviva Lev-Ari Contribution Confidential Confidential 14+ years of core IP creation and leadership
Subtotal before Adjustment Confidential — —
Adjustments (net) Confidential — Conservative balancing adjustment
GRAND TOTAL $650 Million 100% Locked conservative midpoint with full synergistic uplift

Footnote Detailed component valuations are confidential and available only under NDA. The locked enterprise value of the LPBI portfolio is $650 Million. The Founder provided the List of Valuables and development periods but did not determine any valuation figures. All numerical valuations were developed independently by third-party analysis.

 

CHART to be replaced in July 2026

CHART does not include COM – Part 14 and COM – Part 15 – Will be updated in April 2026. 

⚙️ + 💰  COM 15 Parts: From foundational SOPs → multimodal execution infrastructure → validation → monetization → SLM-to-LLM transition → autonomous 24/7 updating (Part 14) → Rosetta Stone Ontology & recursive discovery factories (Part 15) → MFMH.

Parts 1–10  → Part 11  → Part 12  → Part 13 →

Part 14  → Part 15 → MFMH

Composition of Methods: Tools Factory, Part 1 – 10, 11, 12, 13, 14, 15



AI BRAIN <–> COM Part 13 → Part 14  → Part 15

Multimodal Foundation Model in Healthcare

 

SOURCES

See, Slides for Appendices 22, 23

  • 2026 Appendices to Every Slide N = 23 [password protected]

See, details of Portfolio of IP Assets

https://pharmaceuticalintelligence.com/2025/12/08/valuation-models-per-ten-digital-ip-asset-classes-in-lpbi-groups-portfolio-of-ip/

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,037 other subscribers
  • Recent Posts

    • Novartis and Bristol Myers Squibb halt CAR-T trial for autoimmune diseases over patient deaths: a potential issue with cell-based manufacturing September 15, 2026
    • FDA Contemplates Changes in Trial Design, Drug Development, and Use of AI in Clinical Trials September 15, 2026
    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...
%d